NEW YORK, NY / ACCESSWIRE / May 14, 2015 / Amarantus BioScience Holdings, Inc. (PINKSHEETS: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's Independent Director, Joseph Rubinfeld, PhD. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Speaking of the vast potential for MANF across areas such as opthalmology, neurology, otology, cardiology, and metabolism, Dr. Rubinfeld explains the importance of the initiation of clinical grade manufacturing has on the initiation of IND-enabling studies, thus the true value creation for the entire MANF pipeline. In regards to Amarantus' newly announced manufacturing agreement with Catalent Biologics, Dr. Rubinfeld wrote, "Before this major step forward MANF was a wish, now it is on the path to becoming a reality." Read the full blog post from Dr. Rubinfeld on TheChairmansBlog.com (http://www.thechairmansblog.com/amarantus-bioscience/joseph-rubinfeld/manf-begins-march-towards-clinic/).

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS' Diagnostics division owns the rights to MSPrecise(R), a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test(R)) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard(TM)) that led to MANF's discovery.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: TheChairmansBlog.com